A company still losing money with steady sales, with high risk. Institutions are adding.
Facts from SEC filings, not a recommendation.
From RCT's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Move the sliders to your own view of RCT. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).
What today's price needs: with a 10% margin and a 15x P/E, sales could shrink about 40% a year for 5 years and still match today's price.
Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.
Price chart by TradingView.
From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, profitable every year, share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.
No open-market insider buys or sells in the last 90 days.
No trades to chart yet.
SEC filings of any kind. 50 means a normal week.
Institutions added 21.1% to their holdings. 6 bought, 4 sold.
No open-market buys or sells in the last 2 insider filings. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
74,000 shares at $2.50 · $185K
2,500,000 shares at $0.25 · $625K
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page